Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 138

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 15
Chunk 138
---
297)  (8,807,573)Income tax expense  -   - Net loss $(42,297) $(8,807,573)         Basic and diluted loss per share of common stock $(0.00) $(0.15)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these financial statements.

 F-4Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)

               Additional   Deferred     Total   Preferred Stock  Common Stock   Paid in    stock  Accumulated  Stockholders’     Shares    Amount    Shares    Amount    Capital   compensation   Deficit  Equity (Deficit)                          Balance, December 31, 2022  -  $-   60,042,000  $60,042  $32,295,236  $(8,060,983) $(23,807,925) $486,370                                  Amortization of deferred stock compensation   -   -   -   -   -   8,060,983   -   8,060,983 Imputed interest on related party loans  -   -   -   -   3,206   -   -   3,206 Net loss  -   -   -   -   -   -   (8,807,573)  (8,807,573)                                 Balance, December 31, 2023  -   -   60,042,000   60,042   32,298,442   -   (32,615,498)  (257,014)                                 Imputed interest on related party loans  -   -   -   -   4,339   -   -   4,339 Net loss  -   -   -   -   -   -   (42